

A large, light blue circular graphic with a thin blue outline. It contains eight solid blue circular nodes of varying sizes positioned around the perimeter. The text "REVOLUTIONISING CANCER CARE WITH PRECISE RADIATION RISK ASSESSMENT" is centered within the circle in a dark blue, sans-serif font.

REVOLUTIONISING
CANCER CARE
WITH PRECISE
RADIATION RISK
ASSESSMENT

SINFONIA

SINFONIA develops novel methodologies and tools that provide a comprehensive risk appraisal for detrimental effects of radiation exposure on patients, workers, the public, and the environment during the management of cancer patients.

OBJECTIVES

- Develop dose estimation tools based on personalised dosimetry methods, advanced computational tools, powered by artificial intelligence (AI)
- Perform research on individual sensitivity to radiation and susceptibility to Second Malignant Neoplasms (SMN) for risk appraisal in medicine
- Develop a novel patient radiation risk appraisal tool and estimate uncertainties
- Conduct research to support radiation risk appraisal for staff, comforters, the public and the environment
- Develop and operate a platform for dose, imaging and non-imaging data
- Provide multidisciplinary education and training


CONSORTIUM

The multidisciplinary SINFONIA consortium combines the expertise of 14 partners from 8 countries. It includes major universities, research institutes, hospitals and industry partners.



RADIATION RISK APPRAISAL FOR DETRIMENTAL EFFECTS FROM MEDICAL EXPOSURE DURING MANAGEMENT OF PATIENTS WITH LYMPHOMA OR BRAIN TUMOUR

FIRST RESULTS

- An AI-powered web-based toolbox (i-Dose) for estimation of organ doses from X-ray examinations as well as a sophisticated tool for multi-organ segmentation of CT total body scans were developed.
 - A transformer-based deep learning model for voxel-level dosimetry in ^{177}Lu -DOTATATE therapy was trained with Monte Carlo simulations.
 - Out-of-field doses during the treatment of Hodgkin lymphoma and brain tumour patients receiving photon and proton treatments were evaluated.
 - A data repository to share information and the developed AI algorithms was created.
 - The impact from the release of radiopharmaceuticals on humans and the environment was evaluated.
 - Blood samples to determine variability in radiotherapy-induced mutations were collected.
 - A survey on education and training in dosimetry, radiobiology and radiation protection was conducted, and training courses were also organised.
 - An AI-assisted system for real-time staff dose assessment in nuclear medicine is under development.
 - An international multicenter measurement campaign on staff doses in nuclear medicine was finalised to analyse the occupational dose contributions specifically from ^{68}Ga , ^{177}Lu and ^{131}I .
 - An advanced computational framework was developed and benchmarked to estimate the doses to caregivers or family members from nuclear medicine patients in close-contact scenarios.
- 




PROJECT FACTS

Coordinator:	European Institute for Biomedical Imaging Research (EIBIR), AT
Duration:	48 months
Runtime:	1 September 2020 – 31 August 2024
Total EU Funding:	€ 5,999,998.75
Project Manager:	Ulrike Mayerhofer-Schirmer European Institute for Biomedical Imaging Research (EIBIR), AT umayerhofer-schirmer@eibir.org
Scientific Coordinator:	Prof. John Damilakis University of Crete (UoC), GR



This project has received funding from the Euratom research and training programme 2019-2020 under grant agreement No 945196.



Find out more at
sinfonia-appraisal.eu